MYD88 and diffuse large B-cell lymphoma: Interestingly, it has recently been demonstrated that DLBCL with mutant MYD88 exhibited with a macrophage-activating secretion profile through exhibiting elevated CCL2 expression, followed by an increase in macrophage-derived TGF-β1 secretion (31).